ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Renal Clearable Probe for In Vivo Monoamine Oxidase (MAO) Detection.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An ICT + ESIPT synergistic NIR ratiometric probe for mitochondrial MAOs imaging in vivo and in vitro.Analytical and bioanalytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Hyperactivation of monoamine oxidase enzymes (MAO) is associated with uncontrolled production of neurotoxic compounds such as reactive oxygen species, whose accumulation is linked to neurodegenerative, chronic, and age-related diseases. Although chromo-fluorogenic probes for detecting and quantifying MAO activity have been reported, non-invasive methods for monitoring MAO overexpression in vivo remain elusive. Here, we report a renal-clearable fluorogenic probe based on the cyanine-7 fluorophore (Cy7-MAO) for in vivo detection of MAO overexpression through a simple measurement of the fluorescence in urine. The probe incorporates sulfonic acid moieties for renal clearance and a propylamino group as a MAO substrate. Upon administration, Cy7-MAO is hydrolysed at the site by MAO, releasing a highly emissive Cy7 fluorophore, which is excreted in urine and quantified by fluorescence. Cy7-MAO is validated in vitro using HepG2 liver human cells, which express elevated MAO levels. We further demonstrate the in vivo applicability of Cy7-MAO for MAO activity monitoring in aged mice, which show significantly higher urine fluorescence than young mice, consistent with an elevated MAO activity in older animals. These findings support Cy7-MAO as a tool for longitudinal assessment of MAO activity in vivo, providing a novel approach to study MAO-related pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.